- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Lobe Sciences Ltd.: Lobe Sciences Completes Debt Settlement to Improve Balance Sheet | 197 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies... ► Artikel lesen | |
| 09.10. | Lobe Sciences Ltd (2): Lobe Sciences arranges $137,130 (U.S.) debt settlement | 1 | Stockwatch | ||
| 09.10. | Lobe Sciences Ltd.: Lobe Sciences Improves Balance Sheet | 140 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops... ► Artikel lesen | |
| 16.09. | ArcStone US Corp.: Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto | 511 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 15, 2025) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical... ► Artikel lesen | |
| 10.09. | Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025 | 391 | ACCESS Newswire | VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 09.09. | Lobe Sciences Ltd.: Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors | 347 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on... ► Artikel lesen | |
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 15.08. | Lobe Sciences Ltd.: Lobe Sciences Announces the Closing of the Previously Announced Private Placement | 394 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company")... ► Artikel lesen | |
| 29.07. | Lobe Sciences Ltd (2): Lobe Sciences hires ArcStone for advisory services | 1 | Stockwatch | ||
| 29.07. | Lobe Sciences Ltd (2): Lobe Sciences arranges private placement | 2 | Stockwatch | ||
| 29.07. | Lobe Sciences Ltd.: Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes | 441 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences"... ► Artikel lesen | |
| 29.07. | Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory | 419 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases... ► Artikel lesen | |
| 17.07. | Lobe Sciences Ltd (2): Lobe Sciences issues 546,206 shares for debt of $11,596 | 2 | Stockwatch | ||
| 17.07. | Lobe Sciences announces debt settlement | - | Seeking Alpha | ||
| 17.07. | Lobe Sciences Ltd. Announces Debt Settlement | 382 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases... ► Artikel lesen | |
| 08.07. | Lobe Sciences Ltd (2): Lobe Sciences receives European unitary patent | 1 | Stockwatch | ||
| 08.07. | Lobe Sciences Ltd.: Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease | 667 | ACCESS Newswire | European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease.Covers... ► Artikel lesen | |
| 18.06. | Lobe Sciences Ltd.: Lobe Sciences Moves Forward with Development of Conjugated Psilocin Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals | 312 | ACCESS Newswire | New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin$6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical... ► Artikel lesen | |
| 03.06. | Lobe Sciences Ltd (2): Lobe Sciences appoints Yao as CFO, EVP | 3 | Stockwatch | ||
| 03.06. | Lobe Sciences Ltd.: Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth | 343 | ACCESS Newswire | Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth.Mr.... ► Artikel lesen | |
| 14.04. | Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin | 226 | ACCESS Newswire | Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studiesUS$20 Million additional option included in Private Placement to fund the Phase 3 clinical... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,502 | -4,56 % | BioNxt startet 15-tägige Dosisoptimierungsstudie mit sublingualem Cladribin in Vorbereitung auf Bioäquivalenzstudie am Menschen | VANCOUVER, BC / ACCESS Newswire /
21. Oktober 2025 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT) (OTCQB:BNXTF) (FWB:BXT), ein auf innovative
Technologien zur Verabreichung... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| ATAI LIFE SCIENCES | 5,050 | +1,88 % | Analyst Expectations For ATAI Life Sciences' Future | ||
| SOL GLOBAL INVESTMENTS | 0,026 | +9,13 % | SOL Global Investments Corp.: SOL Global Announces Change of Auditor | Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") today announce that it has changed its auditor... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,012 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement | TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing... ► Artikel lesen | |
| CYBIN | 5,400 | +0,93 % | Cybin gibt Update zur Neuropsychiatrie-Plattform und bevorstehenden klinischen Meilensteinen | - Erfolgreich abgeschlossene Aufnahme von 36 Teilnehmern in die Phase-2-Studie zu CYB004, dem DMT-Programm (deuteriertes Dimethyltryptamin, "DMT") des Unternehmens zur
Behandlung der... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics veröffentlicht Update zum Nikotingeschäft und verlängert die Zusammenarbeit - mit einem internationalem Nikotinpartner um sieben Monate. | DJ PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics veröffentlicht Update zum Nikotingeschäft und verlängert die Zusammenarbeit - mit einem internationalem Nikotinpartner um sieben... ► Artikel lesen | |
| NUVALENT | 93,39 | +2,75 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 66,06 | -3,25 % | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | ||
| INHIBRX BIOSCIENCES | 57,29 | +102,01 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARVINAS | 9,210 | +0,66 % | Arvinas reports promising preclinical data for KRAS G12D cancer drug | ||
| NEUPHORIA THERAPEUTICS | 6,260 | +55,34 % | Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,040 | +5,59 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings |
Das Unternehmen LOBE SCIENCES LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,020 Euro und damit -6,98 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.